VAC BNO 1095 FCT

Phase 3Small molecule

BBionorica SE

VAC BNO 1095 FCT is one of 5 small molecule programs targeting Mastodynia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MastodyniaActive, not recruiting

MastodyniaPhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Mastodynia

#DrugCompanyPhaseTrials

Fareston

Kyowa Kirin Co., Ltd.

Voltaren

Danocrine

Aquasol E

NNational Eye Institute (NEI)

VAC BNO 1095 FCT

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Mastodynia2 trials

Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome

Completed·BBionorica SE·Phase 3·NCT01309113·191 enrolled

Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS

Terminated·BBionorica SE·Phase 3·NCT01870687·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VAC BNO 1095 FCT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VAC BNO 1095 FCT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VAC BNO 1095 FCT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bionorica SE company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBionorica SE

VAC BNO 1095 FCT

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Mastodynia2 trials

References

Drug Info

Quick Facts

Related News